𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment Rationale and Study Design for a Randomized Trial of Pemetrexed/Carboplatin Followed by Maintenance Pemetrexed Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced Non–Small-Cell Lung Cancer of Nonsquamous Histology

✍ Scribed by Ralph G. Zinner; Scott B. Saxman; Guangbin Peng; Matthew J. Monberg; Waldo I. Ortuzar

Book ID
119935648
Publisher
CIG Media Group, LP.
Year
2010
Tongue
English
Weight
122 KB
Volume
11
Category
Article
ISSN
1525-7304

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment Rationale and Study Design for
Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer
✍ Jyoti D. Patel; Philip Bonomi; Mark A. Socinski; Ramaswamy Govindan; Shengyan Ho 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 100 KB
PointBreak: A Randomized Phase III Study
PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
✍ Patel, J. D.; Socinski, M. A.; Garon, E. B.; Reynolds, C. H.; Spigel, D. R.; Ols 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 243 KB